Publikationen, an denen er mitarbeitet José Sanz Moreno (7)

2022

  1. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort

    HIV Medicine, Vol. 23, Núm. 8, pp. 825-836

2021

  1. A predictive model and risk factors for case fatality of covid-19

    Journal of Personalized Medicine, Vol. 11, Núm. 1, pp. 1-18

  2. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

2017

  1. Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253

2015

  1. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial

    The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784

2000

  1. Toxicidad de dos pautas posologicas de indinavir. Estudio de cohortes retrospectivo

    Farmacia Hospitalaria, Vol. 24, Núm. 4, pp. 253-257

1996

  1. PREVENCION PRIMARIA Y SECUNDARIA DE LAS COMPLICACIONES INFECCIOSAS EN LOS PACIENTES VIH POSITIVOS

    Inflamacion y Regulacion del Crecimiento Celular, Vol. 7, Núm. 2, pp. 112-121